Magazine
Latest Issue

As vaccines come into view, here’s what you need to know about investing in biotech

The wild ride of the last few weeks may give way to something more stable

Photo: Pixabay

Nothing beats being in the right place at the right time. This year that has proved true in spades. If you were fortunate enough in January to own shares in Novacyt, a tiny company with a test that could detect Covid-19, and you resisted the temptation to sell, you were sitting on a gain of 7,000 per cent by early November: £1,000 became £70,000. This happened because Novacyt itself was in the right place at the right time. Its test launched across Europe in February…

Register today to continue reading

You’ve hit your limit of three articles in the last 30 days. To get seven more, simply enter your email address below.

You’ll also receive our free e-book Prospect’s Top Thinkers 2020 and our newsletter with the best new writing on politics, economics, literature and the arts.

Prospect may process your personal information for our legitimate business purposes, to provide you with our newsletter, subscription offers and other relevant information.

Click here to learn more about these purposes and how we use your data. You will be able to opt-out of further contact on the next page and in all our communications.

We want to hear what you think about this article. Submit a letter to letters@prospect-magazine.co.uk

More From Prospect